Involvement of nitric oxide in phencyclidine-induced hyperlocomotion in mice

European Journal of Pharmacology
Y NodaT Nabeshima

Abstract

The present study was undertaken to investigate the involvement of nitric oxide (NO) in the behaviors induced by 1-(1-phenylcyclohexyl) piperidine (phencyclidine; PCP) in mice, using N(G)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of NO synthase. PCP (1, 3, and 10 mg/kg s.c.) dose dependently induced hyperlocomotion and stereotyped behaviors, including sniffing, head movement, and ataxia, in mice. PCP also caused a marked deficit of motor coordination in mice, the effect being exerted in a dose-dependent manner. Although pretreatment with L-NAME (50 mg/kg i.p.) slightly enhanced the ataxia induced by PCP (3 mg/kg), it failed to modify other stereotyped behaviors and the lack of motor coordination induced by PCP (2 mg/kg). The hyperlocomotion induced by PCP (3 mg/kg) was significantly enhanced by L-NAME (5 and 50 mg/kg) and 7-nitro indazole (25 mg/kg), but not by D-NAME (50 mg/kg), a less active enantiomer of L-NAME. However, the behavioral changes induced by PCP, at the high dose, 10 mg/kg, were not enhanced by L-NAME and D-NAME. The enhancing effects of L-NAME on the PCP (3 mg/kg)-induced hyperlocomotion were significantly prevented by L-arginine (1 g/kg i.p.). However, D-arginine (1 g/kg i.p.) and L-lysine (1 g/kg i...Continue Reading

References

Oct 1, 1991·The American Journal of Psychiatry·D C Javitt, S R Zukin
Dec 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·T J O'DellO Arancio
Jan 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·D S Bredt, S H Snyder
Apr 30, 1990·Biochemical and Biophysical Research Communications·U FörstermannF Murad
Jan 1, 1990·Journal of Neural Transmission. General Section·P I TiedtkeW J Schmidt
Feb 1, 1990·Trends in Pharmacological Sciences·D Lodge, K M Johnson
Jun 1, 1990·Trends in Pharmacological Sciences·H Wachtel, L Turski
Mar 30, 1990·Biochemical and Biophysical Research Communications·M HeckerJ R Vane
Jun 24, 1989·BMJ : British Medical Journal·K Jansen
Jul 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·R G KnowlesS Moncada
Nov 1, 1989·Trends in Pharmacological Sciences·J Collier, P Vallance
Jul 9, 1987·European Journal of Pharmacology·T NabeshimaT Kameyama
Jan 14, 1986·European Journal of Pharmacology·M HiramatsuT Kameyama
Feb 12, 1985·European Journal of Pharmacology·T NabeshimaT Kameyama
Sep 1, 1971·The Journal of Pharmacy and Pharmacology·S R Tonge, B E Leonard
Jan 1, 1972·Psychopharmacologia·E F Domino, A E Wilson
Jul 17, 1981·European Journal of Pharmacology·S Castellani, P M Adams
Jan 1, 1980·Pharmacology, Biochemistry, and Behavior·M K MenonC Vivonia
Oct 1, 1994·Japanese Journal of Pharmacology·K KitaichiT Nabeshima
Jun 1, 1995·Pharmacology, Biochemistry, and Behavior·T A NakamuraT Nabeshima
Oct 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·G A BöhmeJ C Blanchard
Feb 16, 1993·European Journal of Pharmacology·A CalignanoL Sorrentino

❮ Previous
Next ❯

Citations

May 1, 2004·Psychopharmacology·Ming-Huan ChanHwei-Hsien Chen
Jul 29, 2005·Cellular and Molecular Neurobiology·E A Del BelD de Paula-Souza
Nov 1, 2011·Molecular and Cellular Biochemistry·Kechen BanRosemary A Kozar
Nov 18, 2000·Behavioural Brain Research·Y MiyamotoT Nabeshima
Mar 23, 2004·Behavioural Brain Research·Carmen ManzanedoJosé Miñarro
Jul 6, 2000·British Journal of Pharmacology·M Bujas-BobanovicS M Dursun
Aug 11, 2007·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Akihiro MouriToshitaka Nabeshima
Dec 30, 2014·Indian Journal of Pharmacology·İbrahim BaşhanErgin Şingirik
Sep 1, 2005·Basic & Clinical Pharmacology & Toxicology·Eduardo NavarroMiguel A Castellano
Jan 30, 2004·Basic & Clinical Pharmacology & Toxicology·Daniel KlamerLennart Svensson
Dec 24, 2009·Alcoholism, Clinical and Experimental Research·Tara S Bender, Abdel A Abdel-Rahman
Dec 12, 2001·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·E A AfifyM S Abou Zeit-Har
May 20, 2006·Journal of Neuroscience Research·Nikolaos PitsikasNikolaos Sakellaridis
Mar 2, 2006·European Journal of Anaesthesiology·U ErkentM Ilhan
Apr 14, 2018·Pharmacological Reports : PR·Takahiro MizoguchiHideaki Hara
Jul 16, 2019·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Mizuki UchidaYukihiro Noda
Feb 15, 2001·Journal of Medicinal Chemistry·M RowleyP H Hutson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.